MedPath

Improving Supportive Care For Patients With Thoracic Malignancies

Not Applicable
Completed
Conditions
Lung Cancer
Quality of Life
Supportive Care
Interventions
Behavioral: Weekly telephone symptom assessment
Registration Number
NCT03216109
Lead Sponsor
Palo Alto Veterans Institute for Research
Brief Summary

The purpose of this study is to use a proactive approach to improve symptom management of patients with thoracic malignancies and ensure receipt of evidence-based cancer care delivery. In this pilot study, the investigators propose to evaluate the feasibility of using outbound, proactive telephone symptom assessment strategies and ensuring evidence-based care receipt and measure the efficacy of this approach on patient satisfaction with their care, patient activation, quality of life and use of healthcare resources.

Detailed Description

The investigators have previously shown in previous work that patients and caregivers who experience thoracic malignancies express poor symptom management that result in utilization of healthcare resources after-hours for symptoms that could have been prevented if assessed more proactively and prospectively. Currently, there are limited proactive approaches to prospectively identify and intervene on patient-reported symptoms. The purpose of this study is to enhance symptom assessment strategies by using a proactive assessment approach to improve symptom relief for patients with thoracic malignancies.

The investigators will test whether a proactive telephone symptom assessment and management strategy is feasible and can facilitate early patient report of their symptoms and intervention. The knowledge gained from this approach will be used to identify solutions that can be scaled nationally to improve patient-reported symptom management and patient satisfaction with their clinical care.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • All patients with lung cancer treated at VA Palo Alto. This includes all newly diagnosed patients and those under follow-up care.
Exclusion Criteria
  • Patients who do not anticipate receiving oncology care at the VA Palo Alto Health Care System.
  • Patients who are unable to consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Weekly telephone symptom assessmentWeekly telephone symptom assessmentEach patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Symptom assessments will be documented into an encrypted, HIPAA compliant digital platform which provides longitudinal symptom data management and also provides symptom assessment tools for the clinical team in their intervention strategies. In addition, patients will complete symptom and quality of life surveys at 0, 3, 6 and 9 months.
Primary Outcome Measures
NameTimeMethod
Symptom documentation6 months after patient enrollment

Defined as 75% documentation of symptoms for patients in the intervention arm

Secondary Outcome Measures
NameTimeMethod
Emergency Department Visit (Chart Review)9 months after patient enrollment

Emergency Department visits for each patient will be abstracted by electronic medical record for each patient at 9 months

Hospitalizations (Chart Review)9 months after patient enrollment

Hospitalizations for each patient will be abstracted by electronic medical record for each patient at 9 months

Change in Quality of Life using the Functional Assessment of Cancer Therapy - Lung surveyChange in Quality of Life from baseline to month 9

Each patient will receive a validated survey to assess quality of life at baseline and 9 months

Change in patient satisfaction with decision-making using the Satisfaction with Decision SurveyChange in patient satisfaction with decision--making from baseline to 9 months

Each patient will receive a validated survey to assess their satisfaction with decision at baseline and 9 months

Change in Patient Activation using the validated Patient Activation MeasureChange in patient activation from baseline to 9 months

Each patient will receive a validated survey to assess their activation at baseline and 9 months

Change in symptoms using the validated Edmonton Symptom Assessment ScaleChange in symptoms from baseline to 9 months

Each patient will receive a validated survey to assess their symptoms at baseline and 9 months

Trial Locations

Locations (1)

VA Palo Alto Health Care System

🇺🇸

Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath